# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 29, 2015

# ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

Ireland (State or other jurisdiction of incorporation) **001-35299** (Commission File Number) **98-1007018** (IRS Employer Identification No.)

Connaught House, 1 Burlington Road Dublin 4, Ireland

(Address of principal executive offices)

(Zip Code)

## (Registrant's telephone number, including area code): + 353-1-772-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## **TABLE OF CONTENTS**

Item 2.02 Results of Operations and Financial Condition Item 9.01 Financial Statements and Exhibits SIGNATURE EXHIBIT INDEX Ex-99.1 Press release issued by Alkermes plc dated October 29, 2015 announcing financial results for the quarter ended September 30, 2015.

## Table of Contents

## Item 2.02 Results of Operations and Financial Condition

On October 29, 2015. Alkermes plc announced financial results for the quarter ended September 30, 2015. A copy of the press release is attached hereto as Exhibit 99.1. This information, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

## Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit	
No.	Description
99.1	Press release issued by Alkermes plc dated October 29, 2015 announcing financial results for the quarter ended September 30, 2015.

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## ALKERMES PLC

Date: October 29, 2015

By: <u>/s/ James M. Frates</u> James M. Frates Senior Vice President and Chief Financial Officer (Principal Financial Officer)

4

## EXHIBIT INDEX

Exhibit <u>No.</u> 99.1

Description Press release issued by Alkermes plc dated October 29, 2015 announcing financial results for the quarter ended September 30, 2015.

Alkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Jennifer Snyder, +1 781 609 6166

#### ALKERMES PLC REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS

- Third Quarter Revenues of \$152.7 Million and Non-GAAP Diluted Loss Per Share of \$0.18 -

— Commercial Launch of ARISTADA<sup>TM</sup> Underway Following FDA Approval for the Treatment of Schizophrenia on Oct. 5, 2015 —

- ALKS 3831 for Schizophrenia and ALKS 8700 for Multiple Sclerosis to Commence Registration Studies Before Year-End --

**DUBLIN, Ireland, Oct. 29, 2015** — Alkermes plc (NASDAQ: ALKS) today reported financial results for the third quarter of 2015.

"Earlier this month, the FDA approved ARISTADA<sup>™</sup> as the first long-acting atypical antipsychotic for the treatment of schizophrenia with both once-monthly and six-week dosing. Our nationwide commercial launch is underway and we are delighted to bring this important new treatment option to patients and the treatment community," said Richard Pops, Chief Executive Officer of Alkermes. "Alkermes has a number of important milestones ahead that will drive the growth of the company. Based on our recent discussions with the FDA, we have determined the design of the pivotal programs for both ALKS 3831 in schizophrenia and ALKS 8700 in multiple sclerosis and expect to initiate both before year-end. The pivotal program for ALKS 5461 in major depressive disorder is advancing rapidly, and we expect data from the first core efficacy study in the first quarter of 2016."

"We are pleased by our solid financial performance during the third quarter and are on track with our financial expectations for the remainder of 2015. The approval of ARISTADA further strengthens our commercial portfolio and represents a major financial opportunity for Alkermes," commented James Frates, Chief Financial Officer of Alkermes. "Heading into 2016, we are well-positioned to invest in our development plans for our late-stage pipeline, the launch of ARISTADA and drive the growth of VIVITROL<sup>®</sup>."

#### Quarter Ended Sept. 30, 2015 Highlights

•Total revenues for the quarter were \$152.7 million compared to \$160.0 million for the same period in the prior year, or \$143.2 million excluding \$16.8 million of revenues from the products associated with the Gainesville manufacturing facility that was divested in April 2015.

•Net loss according to generally accepted accounting principles in the U.S. (GAAP) was \$81.0 million, or a basic and diluted GAAP loss per share of \$0.54, for the quarter. This compared to GAAP net loss of \$40.0 million, or a basic and diluted GAAP loss per share of \$0.27, for the same period in the prior year, or \$34.5 million, or a basic and diluted loss per share of \$0.24, excluding \$5.5 million of GAAP net income related to the Gainesville facility and associated products.

•Non-GAAP net loss was \$26.2 million, or a non-GAAP diluted loss per share of \$0.18 for the quarter. This compared to non-GAAP net income of \$3.9 million, or a non-GAAP diluted earnings per share of \$0.03, for the same period in the prior year, or a non-GAAP net loss of \$3.5 million, or a non-GAAP basic and diluted loss per share of \$0.02, excluding \$7.4 million of non-GAAP net income related to the Gainesville facility and associated products.

#### Quarter Ended Sept. 30, 2015 Financial Results

Revenues

•Manufacturing and royalty revenues from RISPERDAL CONSTA<sup>®</sup> and INVEGA SUSTENNA<sup>®</sup>/XEPLION<sup>®</sup> were \$67.6 million, compared to \$68.5 million for the same period in the prior year.

•Net sales of VIVITROL were \$37.9 million, compared to \$25.8 million for the same period in the prior year, representing an increase of approximately 47%.

•Manufacturing and royalty revenues from AMPYRA<sup>®</sup>/FAMPYRA<sup>®1</sup> were \$22.1 million, compared to \$16.5 million for the same period in the prior year.

•Royalty revenue from BYDUREON\* was \$13.0 million, compared to \$10.3 million for the same period in the prior year.

#### Costs and Expenses

•Operating expenses were \$230.1 million, reflecting increased investment in the company's rapidly advancing development pipeline and pre-launch activities for ARISTADA, and included \$13.9 million of share-based compensation expense related to the partial vesting of a performance-based equity grant related to the approval of ARISTADA. This compared to \$192.7 million for the same period in the prior year, or \$180.0 million excluding \$12.7 million of operating expenses related to the Gainesville facility and associated products.

Income tax provision was \$3.0 million, compared to \$3.5 million for the same period in the prior year.

#### Balance Sheet

At Sept. 30, 2015, Alkermes had cash and total investments of \$815.5 million, compared to \$801.6 million at Dec. 31, 2014. At Sept. 30, 2015, the company's total debt outstanding was \$353.2 million.

#### **Conference Call**

Alkermes will host a conference call at 8:30 a.m. EDT (12:30 p.m. GMT) on Thursday, Oct. 29, 2015, to discuss these financial results and provide an update on the company. The conference call may be accessed by dialing +1 888 424 8151 for U.S. callers and +1 847 585 4422 for international callers. The conference call ID number is 6037988. In addition, a replay of the conference call will be available from 11:00 a.m. EDT (3:00 p.m. GMT) on Thursday, Oct. 29, 2015, through 5:00 p.m. EST (10:00 p.m. GMT) on Thursday, Nov. 5, 2015, and may be accessed by visiting Alkermes' website or by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for international callers. The replay access code is 6037988.

#### About Alkermes

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

#### **Non-GAAP Financial Measures**

This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including non-GAAP net income or loss, non-GAAP diluted earnings or loss per share and free cash flow. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

Management defines its non-GAAP financial measures as follows:

•Non-GAAP net income or loss adjusts for one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; non-cash tax expense; deferred revenue; and certain other one-time or non-cash items.

· Free cash flow represents non-GAAP net income or loss less capital expenditures.

#### 2

The company's management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, better indicate underlying trends in ongoing operations and cash flows. However, non-GAAP net income or loss, non-GAAP diluted earnings or loss per share and free cash flow are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

#### Note Regarding Forward-Looking Statements

Certain statements set forth above may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to: statements concerning future financial and operating performance, business plans or prospects; the likelihood of continued revenue growth from the company's commercial products; the therapeutic and commercial value of the company's products; and expectations concerning the timing and results of development activities, including the timing of the commencement of the pivotal programs for ALKS 3831 and ALKS 8700 and the receipt of data from the first core efficacy study of ALKS 5461. The company cautions that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the impact of litigation, including litigation against regulatory authorities, in respect of our products; clinical development activities may not be completed on time or at all and the results of such activities may not be predictive of real-world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company, and its partners, may not be able to continue to successfully commercialize its products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the U.S. Food and Drug Administration or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading "Item 1A. Risk Factors" in the company's Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2014 and under the heading "Item 1A. Risk Factors" in the company's Quarterly Report on Form 10-Q for the fiscal quarter ended Sept. 30, 2015, and in any other subsequent filings made by the company with the Securities and Exchange Commission ("SEC"), which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The information contained in this press release is provided by the company as of the date hereof and, except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking information contained in this press release.

ARISTADA<sup>™</sup> is a trademark of Alkermes Pharma Ireland Limited; VIVITROL<sup>®</sup> is a registered trademark of Alkermes, Inc. RISPERDAL CONSTA<sup>®</sup>, INVEGA SUSTENNA<sup>®</sup> and XEPLION<sup>®</sup> are registered trademarks of Johnson & Johnson; AMPYRA<sup>®</sup> and FAMPYRA<sup>®</sup> are registered trademarks of Acorda Therapeutics, Inc.; BYDUREON<sup>®</sup> is a registered trademark of Amylin Pharmaceuticals, LLC.

<sup>1</sup>AMPYRA<sup>\*</sup> (dalfampridine) Extended Release Tablets, 10 mg is developed and marketed in the U.S. by Acorda Therapeutics, Inc. and outside the U.S. by Biogen International GmbH, under a licensing agreement with Acorda Therapeutics, Inc., as FAMPYRA<sup>\*</sup> (prolonged-release fampridine tablets).

(tables follow)

3

# Alkermes plc and Subsidiaries Selected Financial Information (Unaudited)

Revenues: \$114,072 \$152,028   Product sales, net 37,903 25,802   Research and development revenues 678 2,162   Total Revenues 152,653 159,992   Expenses: 78,263 159,992   Cost of goods manufactured and sold 33,806 47,335   Research and development 92,558 78,263   Selling, general and administrative 89,497 51,888   Amorization of acquired intangible assets 14,207 15,244   Total Expenses 230,068 192,2730   Operating Loss (77,415) (32,738)   Other Expense, net: (77,415) (32,738)   Interest income 865 546   Interest acquence, net 629 (921)   Total Other Expense, net 629 (921)   Total Other Expense, net 629 (921)   Total Other Expense, net (63,633) (78,603) (36,643)   Loss Before Income Taxes (78,020) (36,643) 0.03   Net Loss — GAAP \$(0,54) \$(	Condensed Consolidated Statements of Operations - GAAP (In thousands, except per share data)		Three Months Ended September 30, 2015	Three Months Ended September 30, 2014
Product sales, net37,90325,802Research and development revenues6782,162Total Revenues152,653159,992Expenses:33,80647,335Research and development92,55878,263Selling, general and administrative89,49751,888Amortization of acquired intangible assets14,20715,244Total Expenses230,068192,730Operating Loss(77,415)(32,738)Other Expense, net:(77,415)(32,738)Interest income865546Interest income865546Interest income(3,22)(3,356)Gain on sale of property, plant and equipment-36Other Expense, net:(605)(3,695)Loss Before Income Taxes(78,020)(36,6433)Income Taxes(78,020)(36,6433)Income Taxes(78,020)(36,6433)Income Taxes(78,020)(36,6433)Income Taxes(78,020)(36,6433)Income Taxes(78,020)(36,6433)Income Taxes(149,512)145,896Basic — Nor.GAAP(49,512)145,896Basic — Nor.GAAP(49,512)145,896Diluted — Non-GAAP(49,512)145,896Diluted — Non-GAAP(23,42)(34,896)Non-cash taxes6773,640Non-cash taxes6773,640Non-cash taxes6773,640Non-cash taxes6773,640Non-cash taxes<	Revenues:			
Research and development revenues678 152,6532,162 159,992Total Revenues152,653159,992Cost of goods manufactured and sold33,80647,335Research and development92,55878,263Selling, general and administrative84,949751,888Amortization of acquired intangible assets14,20715,244Total Expenses230,068192,730Operating Loss(77,415)(32,738)Other Expense, net:(77,415)(32,738)Interest expense(3,325)(3,356)Gain on safe of property, plant and equipment26-Gots of property, plant and equipment-36Other Expense, net(605)(3,695)Loss Before Income Taxes(78,020)(3,643)Income Tax Provision2,9953,523Net Loss - GAAP(81,015)\$(9,956)(Loss) Earnings Per Share:(6051)(3,695)Cost of Gold Science Interse(9,271)Non-GAAP (Ioss) earnings per share — basic and diluted\$Metized - Non-GAAP149,512145,896Diluted - Non-GAAP149,512145,896Diluted - Non-GAAP149,512145,896Diluted - Non-GAAP149,512145,896Diluted - Non-GAAP149,512145,896Diluted - Non-GAAP149,512145,896Diluted - Non-GAAP149,512145,896An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)154,499Non-cash taxes <td< td=""><td>Manufacturing and royalty revenues</td><td>\$</td><td></td><td></td></td<>	Manufacturing and royalty revenues	\$		
Total Revenues152,653159,992Expenses:152,653159,992Expenses:33,80647,335Research and development92,55878,263Selling, general and administrative89,49751,888Amorization of acquired intangible assets14,20715,244Total Expenses230,0068192,730Operating Loss(77,415)(32,738)Other Expense, net:33,255(3,356)Interest income865546Interest pense(3,325)(3,356)Gain on the Gainesville Transaction1,200-Interest expense(3,325)(3,356)Gain on sale of property, plant and equipment-36Other income (expense), net(605)(3,692)Loss Defore Income Taxes(78,200)(36,433)Income Tax Provision2,9953,523Net Loss – GAAP\$(0,151)\$Non-GAAP (loss) earnings per share — basic and diluted\$(0,151)\$Net Loss – GAAP149,512145,896Diluted — Non-GAAP149,512145,896Diluted — Non-GAAP149,512145,896Diluted — Non-GAAP142,071154,481Amoritarion expense32,66713,481Amoritario expense64,869,989Non-cash taxes6773,640Non-cash taxes6773,640Non-cash taxes6773,640Non-cash taxes6773,640Non-cash taxes677<	Product sales, net		-	
Expenses:33,80647,335Cost of goods manufactured and sold33,80647,335Research and development92,55878,263Selling, general and administrative89,49751,888Amoritzation of acquired intangible assets14,20715,244Total Expenses230,068192,730Operating Loss(77,115)(32,738)Other Expense, net:77,415(32,738)Interest expense(3,325)(3,355)Gain on the Gainesville Transaction26-Interest expense(3,325)(3,355)Gain on all of property, plant and equipment-35Other Expense, net:(605)(3,695)Loss Before Income Taxes(78,020)(36,433)Income Tax Provision2,9953,523Net Loss — GAAP(3,115)\$(39,956)(Loss) Earnings Per Share:(0,54)\$(0,27)Non-GAAP (loss) earnings per share — basic and diluted\$(0,18)\$Diluted — Non-GAAP149,512145,896Diluted — Non-GAAP149,512145,896Diluted — Non-GAAP149,512145,896Diluted — Non-GAAP142,07115,244Amoritzation expense32,26713,481Amoritzation expense64,869,989Non-cash taxes6773,640Non-cash taxes6773,640Non-cash taxes6773,640Non-cash taxes6373,640Non-cash taxes6773,640 <td>Research and development revenues</td> <td>_</td> <td></td> <td></td>	Research and development revenues	_		
Cost of goods manufactured and sold33.80647,335Research and development92,55878,263Selling, general and administrative89,49751,888Amortization of acquired intangible assets14,20715,244Total Expenses230,068192,730Operating Loss(77,415)(32,738)Other Expense, net:865546Interest income865546Interest income3,320(3,350)Other income (expense), net62(921)Total Expense, net:605(3,695)Increase in the fair value of contingent consideration1,200-Gain on sale of property, plant and equipment-35Other income (expense), net(605)(3,645)Loss Before Income Taxes(78,020)(36,433)Income Tax Provision2,2953,523Net Loss - GAAP§(81,015)(0,27)Non-GAAP (loss) earnings per share - basic and diluted\$(0,54)(0,27)Non-GAAP (loss) earnings per share - basic and diluted\$(0,54)(0,27)Neighted Average Number of Ordinary Shares Outstanding:149,512145,896Basic – Non-GAAP149,512145,896Basic – Non-GAAP5(31,415)(39,956)An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)149,512145,896Income as follow:32,242154,399134,81Marcharebased compensation expense32,242238Net Loss – GAAP </td <td>Total Revenues</td> <td>_</td> <td>152,653</td> <td>159,992</td>	Total Revenues	_	152,653	159,992
Research and development92,55878,263Selling, general and administrative89,49751,888Anortization of acquired intagible assets14,20715,244Total Expenses230,068192,730Operating Loss $(77,415)$ (32,738)Other Expense, net:865546Interest expense(3,325)(3,356)Gain on she of property, plant and equipment-36Other Expense, net:665(3,695)Total Other Expense, net(605)(3,695)Loss Before Income Taxes(78,020)(36,433)Income (expense), net(605)(3,695)Loss Before Income Taxes(78,020)(36,433)Income Tax Provision2,9953,523Net Loss - GAAP\$(81,015)\$(Loss) Earnings Per Share: $(0.54)$ \$(Loss) Earnings per share - basic and diluted\$ $(0.27)$ Non-GAAP (loss) earnings per share - basic and diluted\$ $(0.21)$ Pasic and diluted - GAAP149,512145,896Basic - Non-GAAP149,512145,896Diluted - Non-GAAP149,512145,896Non-cash net interset expense35,26713,481An ortization expense35,26713,481An ortization expense6,4869,989Non-cash net interset expense6,3649,959Non-cash net interset expense6,3649,989Non-cash net interset expense6,3649,989Non-cash net interset expense6,36<				
Selling, general and administrative $89,497$ $51,888$ Amortization of acquired intangible assets14,20715,244Total Expenses $230,068$ 192,730Operating Loss(77,415)(32,738)Other Expense, net:(77,415)(32,738)Interest income $865$ 546Increase in the fair value of contingent consideration1,200.Increase in the fair value of contingent consideration1,200.Gain on ale of property, plant and equipment-36Other income (expense), net(605)(3,695)Loss Before Income Taxes(78,020)(36,433)Income Tax Provision2,9953,523Net Loss - GAAP\$ (81,015) \$ (39,956)(Loss) Earnings Per Share:.GAAP loss per share — basic and diluted\$ (0,54) \$ (0,27)Non-GAAP (loss) earnings per share — basic and diluted\$ (0,54) \$ (0,27)Non-GAAP (loss) earnings per share — basic and diluted\$ (0,54) \$ (0,27)Non-GAAP149,512145,896Basic — Non-GAAP149,512145,896Diluted — Non-GAAP149,512145,896Diluted — Non-GAAP\$ (81,015) \$ (39,956)Adjustments:Share-based compensation expense35,267An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)income is as follows:.Non-cash net interest expense.Other interest expense <td></td> <td></td> <td></td> <td></td>				
Amorization of acquired intangible assets14.20715.244Total Expenses230.068192.730Other Expense, net:(77.415)(32.738)Interest income865546Interest spense, net:865546Interest spense(3.325)(3.356)Gain on the Gainesville Transaction26-Increase in the fair value of contingent consideration1,200-Gain on sale of property, plant and equipment-36Other income (expense), net(605)(3.695)Loss Before Income Taxes(78,020)(36,433)Income Tax Provision2,9953.523Net Loss - GAAP\$ (0.51) \$ (0.27)Non-GAAP (loss) earnings per share — basic and diluted\$ (0.27)Non-GAAP (loss) earnings per share — basic and diluted\$ (0.18) \$ (0.27)Non-GAAP (loss) earnings per share — basic and diluted\$ (0.18) \$ (0.27)Non-GAAP (loss) earnings per share — basic and diluted\$ (0.18) \$ (0.27)Non-GAAP (loss) earnings per share — basic and diluted\$ (0.18) \$ (0.27)Non-GAAP149,512145,896Diluted — Non-GAAP149,512145,896Diluted — Non-GAAP149,512145,896Non-GAAP149,512154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)13,241Non-cash net interest expense35,26713,481Amorization expense6,4769,989Non-cash net interest expense6,3649,989Non-cash net interest ex				
Total Expenses230,068192,730Operating Loss $(77,415)$ $(23,738)$ Operating Loss $(77,415)$ $(23,738)$ Other Expense, net: $(77,415)$ $(23,738)$ Interest expense $(3,325)$ $(3,356)$ Gain on Ke Gainesville Transaction $1,200$ $-$ Increase in the fair value of contingent consideration $1,200$ $-$ Gain on sale of property, plant and equipment $ 36$ Other income (expense), net $629$ $(921)$ Total Other Expense, net $(605)$ $(3,695)$ Loss Before Income Taxes $(605)$ $(3,695)$ Income Tax Provision $2,995$ $3,523$ Net Loss — GAAP $2,995$ $3,523$ Net Loss — GAAP $(0.54) \le$ $(0.77)$ Non-GAAP (loss) earnings per share — basic and diluted $$ (0.54) \le$ $(0.77)$ Non-GAAP149,512145,896Basic — Non-GAAP149,512145,896Diluted — Non-GAAP $149,512$ 145,896Note Loss — GAAP $$ (81,015) \$$ $$ (39,956)$ Adjustments: $$ (22,730) = (23,975)$ $$ (32,975) = (23,975)$ Adjustments: $$ (32,975) = (32,975) = (32,975)$ $$ (32,975) = (32,975) $			-	
Operating Loss $(77,415)$ $(32,738)$ Other Expense, net: $(3,325)$ $(3,356)$ Interest income $865$ $546$ Interest expense $(3,325)$ $(3,356)$ Gain on the Gainesville Transaction $1,200$ $.6605)$ Increase in the fair value of contingent consideration $1,200$ $.6055)$ Gain on sale of property, plant and equipment $.6055)$ $.(3,695)$ Loss Before Income (expense), net $.6055)$ $.(3,695)$ Loss Before Income Taxes $.(78,020)$ $.(36,433)$ Income Tax Provision $2,995$ $3,523$ Net Loss — GAAP $$(81,015)$ $$(9,956)$ (Loss) Earnings Per Share: $.(80,018)$ $$(0.27)$ Non-GAAP (loss) earnings per share — basic and diluted $$(0.27)$ $$(0.27)$ Non-GAAP (loss) earnings per share — basic and diluted $$(0.18)$ $$(0.27)$ Non-GAAP $$(149,512)$ $$(145,896)$ Diluted — Non-GAAP $$(149,512)$ $$(145,896)$ Diluted — Non-GAAP $$(149,512)$ $$(145,896)$ Diluted — Non-GAAP $$(149,512)$ $$(145,896)$ Not-cash larves $$(77)$ $$(36,433)$ Non-cash taxes $$(77)$ $$(32,738)$ Non-cash taxes $$(77)$ $$(34,738)$ Non-cash taxes $$(77)$ $$(34,738)$ Increase in the fair value of contingent consideration $$(12,92)$ Increase in the fair value of contingent consideration $$(12,92)$ Increase in the fair value of contingent consideration $$(12,92)$ On-cash	Amortization of acquired intangible assets	_		
Other Expense, net: Interest expense865546Interest expense $(3,325)$ $(3,356)$ Gain on the Gainesville Transaction26.Increase in the fair value of contingent consideration1,200.Gain on sale of property, plant and equipmentCoher income (expense), netIoss Before Income TaxesIncome Tax ProvisionNormed AP Poss per shareGAAP loss per share — basic and diluted\$.Non-GAAP (loss) earnings per share — basic and diluted\$.Weighted Average Number of Ordinary Shares Outstanding: Basic — Non-GAAPBasic and diluted — GAAPAnd post share shollow the net loss on a GAAP basis and non-GAAP net (loss)Non-GAAP interizeAdjustments:Share-based compensation expenseAdjustments:Share-based compensation expenseAdjustments:Share-based compensation expenseAdjustments: </td <td>Total Expenses</td> <td>_</td> <td></td> <td></td>	Total Expenses	_		
Interest income865546Interest expense $(3,325)$ $(3,356)$ Gain on the Gainesville Transaction26-Increase in the fair value of contingent consideration1,200-Gain on sale of property, plant and equipment-36Other income (expense), net629 $(201)$ Total Other Expense, net(605) $(3,695)$ Loss Before Income Taxes $(78,020)$ $(36,433)$ Income Tax Provision2,995 $3,523$ Net Loss - GAAP\$(81,015) \$ $(39,956)$ (Loss) Earnings Per Share:GAAP loss per share — basic and diluted\$ $(0.18)$ \$ $0.03$ Weighted Average Number of Ordinary Shares Outstanding:Basic - Non-GAAP149,512145,896-Diluted - Non-GAAP149,512145,896-Diluted - Non-GAAP149,512145,896-Not-GAAP149,512145,896-Matter econciliation between net loss on a GAAP basis and non-GAAP net (loss)Income is as follows:\$(81,015) \$(39,956)Not-cash taxes6773,640Non-cash net interest expense234238-Deferred revenue(725)606Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(26)Increase in the fair value of contingent consideration(120) <td< td=""><td></td><td>_</td><td>(77,415)</td><td>(32,738)</td></td<>		_	(77,415)	(32,738)
Interest expense $(3,325)$ $(3,356)$ Gain on the Gainesville Transaction26-Increase in the fair value of contingent consideration1,200-Gain on sale of property, plant and equipment-36Other income (expense, net629(921)Total Other Expense, net(665)(3,695)Loss Before Income Taxe(78,020)(36,433)Income Tax Provision2,9953,523Net Loss - GAAP\$(81,015)\$(Loss) Bernings Per Share:(0.54)\$(0.27)Non-GAAP (loss) earnings per share — basic and diluted\$(0.18)\$(0.03)Weighted Average Number of Ordinary Shares Outstanding:149,512145,896149,512145,896Basic — Non-GAAP149,512145,896149,512145,896149,512154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)income is as follows:35,26713,481Amortization expense35,26713,481Amortization expense64,869,989Non-cash taxes6773,64014,20715,244238Deferred revenue(725)666142,07603Non-cash taxes6773,64014,20715,244Non-cash taxes6773,64014,207603Non-cash taxes6773,64014,207603Non-cash taxes6773,64014,207603Non-cash taxes6773,640100-<				
Gain on the Gainesville Transaction $26$ Increase in the fair value of contingent consideration $1,200$ Gain on sale of property, plant and equipment $-36$ Other income (expense), net $629$ Income Taxes $(605)$ Income Taxes $(78,020)$ Income Taxes $(91,020)$ Income Taxes $(149,512)$ ItaxItaxBasic and dilutedSIncome CaAP $(149,512)$ ItaxItaxBasic and Other Data $(149,512)$ ItaxItaxItax $(149,512)$ ItaxItaxItax $(149,512)$ ItaxItaxItax $(140,01)$ Itax $($				
Increase in the fair value of contingent consideration1,200-Gain on sale of property, plant and equipment-36Other income (expense), net629(921)Total Other Expense, net(605)(3,695)Loss Before Income Taxes(78,020)(36,433)Income Tax Provision2,9953,523Net Loss — GAAP\$(81,015)\$GAP loss per share — basic and diluted\$(0.54)\$MonGAAP (loss) earnings Per Share:Gata P loss per share — basic and diluted\$(0.18)\$Meighted Average Number of Ordinary Shares Outstanding:Basic — Non-GAAP149,512145,896-Diluted — Non-GAAP149,512145,896-Diluted — Non-GAAP149,512145,896-Non-GAAP (loss) income is as follows:\$(81,015)\$Net Loss — GAAP\$\$(81,015)\$An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)An itemized reconciliation pepese35,26713,481Amortization expense6,4869,989Non-cash net interest expense234234234Deferred revenue(725)696Net (gain) loss on transaction swith equity method investee(397)603Gain on sale of property, plant and equipment(36)Non-cash net interest expense318				(3,356)
Gain on sale of property, plant and equipment36Other income (expense), net629Total Other Expense, net(605)Loss Before Income Taxes(78,020)Income Tax Provision2,9953,523Net Loss — GAAPS(81,015)(Loss) Earnings Per Share:(0.54)GAAP loss per share — basic and diluted\$(Loss) Earnings Per Share:(0.18)GAAP loss per share — basic and diluted\$(Loss) Earnings per share — basic and diluted\$(Loss) Ea				-
Other income (expense), net $629$ $(921)$ Total Other Expense, net $(605)$ $(3,695)$ Loss Before Income Taxes $(78,020)$ $(36,433)$ Income Tax Provision $2,995$ $3,523$ Net Loss - GAAP\$ $(81,015)$ \$ $(39,956)$ (Loss) Earnings Per Share: $(0.54)$ \$ $(0.54)$ GAAP loss per share — basic and diluted\$ $(0.54)$ \$ $(0.27)$ Non-GAAP (loss) earnings per share — basic and diluted\$ $(0.18)$ \$ $0.03$ Weighted Average Number of Ordinary Shares Outstanding:Basic and diluted — GAAP149,512Basic and diluted — GAAP149,512145,896Diluted — Non-GAAP149,512145,896Diluted — Non-GAAP149,512154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)income is as follows:Net Loss — GAAP\$ (81,015) \$ (39,956)Adjustments:S $6,486$ Share-based compensation expense $35,267$ $13,481$ Amortization expense $6,486$ $9,989$ Non-cash net interest expense $234$ $238$ Deferred revenue $(725)$ $696$ Net (gain) loss on transactions with equity method investee $(397)$ $603$ Gain on the Gainesville Transaction $(1,200)$ -Change in the fair value of contingent consideration $(1,200)$ -Change in the fair value of contingent consideration $(1,200)$ -Change in the fair value of contingent consideration $(1,200)$ -Change in the			1,200	-
Total Other Expense, net(605)(3,695)Loss Before Income Taxes(78,020)(36,433)Income Tax Provision2,9953,523Net Loss — GAAP\$(81,015)\$(Loss) Earnings Per Share: $(0.54)$ \$(0.27)Non-GAAP (loss) earnings per share — basic and diluted\$ $(0.18)$ \$0.03Weighted Average Number of Ordinary Shares Outstanding: $(0.84)$ \$0.03Basic and diluted — GAAP149,512145,896149,512145,896Diluted — Non-GAAP149,512145,896149,512154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$(81,015)\$(39,956)Net Loss — GAAP\$149,512154,399154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$(39,956)Net Loss — GAAP\$(4869,989Non-cash taxes6773,640Non-cash taxes6773,640Non-cash taxes6773,640Non-cash taxes637)603Gain on the Gainesville Transaction(1200)-Increase in the fair value of common stock warrants318-Gain on sale of property, plant and equipment-(36)Non-CaAP Net (Loss) Income\$(26,174)\$An expenditures11,9748,888			-	
Loss Before Income Taxes(78,020)(36,433)Income Tax Provision2,9953,523Net Loss — GAAP\$(81,015)\$(Loss) Earnings Per Share:(81,015)\$(0.27)(GAAP loss) earnings per share — basic and diluted\$ $(0.18)$ \$(0.27)Non-GAAP (loss) earnings per share — basic and diluted\$ $(0.18)$ \$(0.03)Weighted Average Number of Ordinary Shares Outstanding:149,512145,896Basic — Non-GAAP149,512145,896Diluted — Non-GAAP149,512154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)149,512154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)(39,956)(39,956)Adjustments:Share-based compensation expense35,26713,481Amortization expense6,4869,9899,899Non-cash taxes6773,640149,215152,244Depreciation expense234238238234238Deferred revenue(725)696423238Non-cash taxes(397)603603631-Gain on the Gainesville Transaction(1,200)Increase in the fair value of contingent consideration(1,200)Increase in the fair value of contingent consideration(1,200)Gain on sale of property, plant and equipment-(36)-Gain on sale of property, plant an		_		
Income Tax Provision2,9953,523Net Loss — GAAP\$2,9953,523Net Loss — GAAP\$(81,015)\$(39,956)(Loss) Earnings Per Share:\$(0.54)\$(0.27)Non-GAAP (loss) earnings per share — basic and diluted\$(0.18)\$0.03Weighted Average Number of Ordinary Shares Outstanding:Basic and diluted — GAAP149,512145,896Basic — Non-GAAP149,512145,896149,512145,896Diluted — Non-GAAP149,512154,399154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$(81,015)\$(39,956)Net Loss — GAAP\$(81,015)\$(39,956)Adjustments:\$5(81,015)\$(39,956)Share-based compensation expense35,26713,481Amortization expense6,4869,989Non-cash taxes6773,640Non-cash taxes6773,640Non-cash taxes6773,640Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(26)-Increase in the fair value of contingent consideration318-Gain on sale of property, plant and equipment-33,899Capital expenditures\$(26,174)\$3,889	Total Other Expense, net	_		
Net Loss — GAAP\$(81,015)\$(39,956)(Loss) Earnings Per Share: GAAP loss per share — basic and diluted\$(0.54)\$(0.27)Non-GAAP (loss) earnings per share — basic and diluted\$(0.18)\$(0.27)Non-GAAP (loss) earnings per share — basic and diluted\$(0.18)\$(0.27)Basic and diluted — GAAP149,512145,896149,512145,896Basic — Non-GAAP149,512145,896149,512154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)149,512154,399Net Loss — GAAP\$(81,015)\$(39,956)Adjustments:\$\$14,20715,244Depreciation expense\$\$234238Non-cash taxes677\$\$64869,989Non-cash taxes677\$\$603Deferred revenue(725)696696149,71603Gain on the Gainesville Transaction(1,200)(36)Non-GAAP Net (Loss) Income\$(26,174)\$3,899Capital expenditures\$\$(26,174)\$3,899	Loss Before Income Taxes	_		
(Loss) Earnings Per Share: GAAP loss per share — basic and diluted\$ $(0.54)$ \$ $(0.27)$ Non-GAAP (loss) earnings per share — basic and diluted\$ $(0.18)$ \$ $(0.27)$ Non-GAAP (loss) earnings per share — basic and diluted\$ $(0.18)$ \$ $(0.27)$ Basic and diluted — GAAP149,512145,896Basic — Non-GAAP149,512145,896Diluted — Non-GAAP149,512154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)income is as follows:Net Loss — GAAP\$(81,015)\$(39,956)Adjustments:\$\$14,20715,244Depreciation expense35,26713,481Amortization expense64,4869,989Non-cash taxes6773,640Non-cash taxes6773,640Non-cash taxes6773,640Non-cash in thinterest expense234238Deferred revenue(725)696Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(1,200)-Change in the fair value of contingent consideration11,200-Change in the fair value of contingent consideration-(36)Non-GAAP Net (Loss) Income\$(26,174)\$Again on sale of property, plant and equipmentCapital expenditures11,974\$,888	Income Tax Provision	_		- 3
GAAP loss per share — basic and diluted\$ (0.21)\$ (0.27)Non-GAAP (loss) earnings per share — basic and diluted\$ (0.18)\$ (0.18)Weighted Average Number of Ordinary Shares Outstanding:Image: Constraint of Constraints of Constra	Net Loss — GAAP	\$	(81,015) \$	(39,956)
GAAP loss per share — basic and diluted\$ (0.21)\$ (0.27)Non-GAAP (loss) earnings per share — basic and diluted\$ (0.18)\$ (0.18)Weighted Average Number of Ordinary Shares Outstanding:Image: Constraint of Constraints of Constra				
Non-GAAP (loss) earnings per share — basic and diluted\$ (0.18) \$ 0.03Weighted Average Number of Ordinary Shares Outstanding: Basic and diluted — GAAP149,512145,896Basic — Non-GAAP149,512145,896Diluted — Non-GAAP149,512145,896Diluted — Non-GAAP149,512154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$ (81,015) \$ (39,956)Net Loss — GAAP\$ (81,015) \$ (39,956)Adjustments: Share-based compensation expense35,26713,481Amortization expense6,4869,989Non-cash taxes6773,640Non-cash net interest expense234238Deferred revenue(725)696Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(1,200)-Change in the fair value of contingent consideration318-Gain on sale of property, plant and equipment-(36)Non-GAAP Net (Loss) Income\$ (26,174) \$ 3,899Capital expenditures11,9748,888		¢	(0.54) ¢	(0.27)
Weighted Average Number of Ordinary Shares Outstanding:Basic and diluted — GAAP149,512145,896Basic — Non-GAAP149,512145,896Diluted — Non-GAAP149,512145,896Diluted — Non-GAAP149,512154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)149,512154,399Net Loss — GAAP\$ (81,015) \$ (39,956)35,26713,481Adjustments:35,26713,481Share-based compensation expense35,26713,481Amortization expense6,4869,989Non-cash taxes6773,640Non-cash net interest expense234238Deferred revenue(725)696Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(1,200)-Change in the fair value of contingent consideration(1,200)-Change in the fair value of common stock warrants318-Gain on sale of property, plant and equipment-(36)Non-GAAP Net (Loss) Income\$ (26,174) \$ 3,899Capital expenditures11,9748,888	*			
Basic and diluted — GAAP149,512145,896Basic — Non-GAAP149,512145,896Diluted — Non-GAAP149,512145,896Diluted — Non-GAAP149,512154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$ (81,015) \$ (39,956)Net Loss — GAAP\$ (81,015) \$ (39,956)Adjustments:\$ (81,017) \$ (39,956)Share-based compensation expense35,267I 14,20715,244Depreciation expense6,4869,989Non-cash taxesNon-cash taxes6773,640Non-cash taxesDeferred revenue(725)Met (gain) loss on transactions with equity method investee(397)Gain on the Gainesville Transaction(26)Increase in the fair value of contingent consideration318Gain on sale of property, plant and equipment-Non-GAAP Net (Loss) Income\$ (26,174) \$ 3,899Capital expenditures11,9748,888	Non-GAAP (loss) earnings per share — basic and diluted	\$	(0.18) \$	0.03
Basic and diluted — GAAP149,512145,896Basic — Non-GAAP149,512145,896Diluted — Non-GAAP149,512145,896Diluted — Non-GAAP149,512154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$ (81,015) \$ (39,956)Net Loss — GAAP\$ (81,015) \$ (39,956)Adjustments:\$ (81,017) \$ (39,956)Share-based compensation expense35,267I 14,20715,244Depreciation expense6,4869,989Non-cash taxesNon-cash taxes6773,640Non-cash taxesDeferred revenue(725)Met (gain) loss on transactions with equity method investee(397)Gain on the Gainesville Transaction(26)Increase in the fair value of contingent consideration318Gain on sale of property, plant and equipment-Non-GAAP Net (Loss) Income\$ (26,174) \$ 3,899Capital expenditures11,9748,888	Weighted Average Number of Ordinary Shares Outstanding:			
Basic — Non-GAAP149,512145,896Diluted — Non-GAAP149,512154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$ (81,015) \$ (39,956)Net Loss — GAAP\$ (81,015) \$ (39,956)Adjustments:35,26713,481Amortization expense35,26713,481Depreciation expense6,4869,989Non-cash taxes6773,640Non-cash net interest expense234238Deferred revenue(725)696Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(1,200)-Increase in the fair value of contingent consideration(1,200)-Change in the fair value of common stock warrants318-Gain on sale of property, plant and equipment-(36)Non-GAAP Net (Loss) Income\$ (26,174) \$ 3,899Capital expenditures11,9748,888			149,512	145,896
DilutedNon-GAAP149,512154,399An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$ (81,015) \$ (39,956)Net LossGAAP\$ (81,015) \$ (39,956)Adjustments:35,26713,481Amortization expense35,26713,481Amortization expense64,869,989Non-cash taxes6773,640Non-cash net interest expense234238Deferred revenue(725)696Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(1,200)-Increase in the fair value of contingent consideration318-Gain on sale of property, plant and equipment-(36)Non-GAAP Net (Loss) Income\$ (26,174) \$ 3,8993,899Capital expenditures11,9748,888			149,512	145,896
An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$ (81,015) \$ (39,956)Net Loss - GAAP Adjustments: Share-based compensation expense\$ (81,015) \$ (39,956)Adjustments: Share-based compensation expense35,26713,481Amortization expense14,20715,244Depreciation expense6,4869,989Non-cash taxes6773,640Non-cash net interest expense234238Deferred revenue(725)696Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(1,200)-Increase in the fair value of contingent consideration318-Gain on sale of property, plant and equipment-(36)Non-GAAP Net (Loss) Income\$ (26,174) \$ 3,8993,899Capital expenditures11,9748,888				
income is as follows:\$ (81,015) \$ (39,956)Net Loss — GAAP\$ (81,015) \$ (39,956)Adjustments:35,267Share-based compensation expense35,267Idage and the expense14,207Depreciation expense6,486Depreciation expense6,486Non-cash taxes677Non-cash net interest expense234Deferred revenue(725)Gain on the Gainesville Transaction(26)Increase in the fair value of contingent consideration(1,200)Change in the fair value of common stock warrants318Gain on sale of property, plant and equipment-Mon-GAAP Net (Loss) Income\$ (26,174) \$ 3,899Capital expenditures11,974State11,974State11,974	Diluitu — Noil-OAAF		119,012	101,000
Adjustments:35,26713,481Amortization expense14,20715,244Depreciation expense6,4869,989Non-cash taxes6773,640Non-cash net interest expense234238Deferred revenue(725)696Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(26)-Increase in the fair value of contingent consideration(1,200)-Change in the fair value of common stock warrants318-Gain on sale of property, plant and equipment-(36)Non-GAAP Net (Loss) Income§(26,174)\$Capital expenditures11,9748,888				
Share-based compensation expense35,26713,481Amortization expense14,20715,244Depreciation expense6,4869,989Non-cash taxes6773,640Non-cash net interest expense234238Deferred revenue(725)696Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(26)-Increase in the fair value of contingent consideration(1,200)-Change in the fair value of common stock warrants318-Gain on sale of property, plant and equipment-(36)Non-GAAP Net (Loss) Income\$ (26,174) \$ 3,899Capital expenditures11,9748,888	Net Loss — GAAP	\$	(81,015) \$	(39,956)
Amortization expense14,20715,244Depreciation expense6,4869,989Non-cash taxes6773,640Non-cash net interest expense234238Deferred revenue(725)696Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(26)-Increase in the fair value of contingent consideration(1,200)-Change in the fair value of common stock warrants318-Gain on sale of property, plant and equipment-(36)Non-GAAP Net (Loss) Income\$ (26,174) \$ 3,899Capital expenditures11,9748,888	5			
Depreciation expense6,4869,989Non-cash taxes6773,640Non-cash net interest expense234238Deferred revenue(725)696Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(26)-Increase in the fair value of contingent consideration(1,200)-Change in the fair value of common stock warrants318-Gain on sale of property, plant and equipment-(36)Non-GAAP Net (Loss) Income\$ (26,174) \$ 3,899Capital expenditures11,9748,888				
Non-cash taxes6773,640Non-cash net interest expense234238Deferred revenue(725)696Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(26)-Increase in the fair value of contingent consideration(1,200)-Change in the fair value of common stock warrants318-Gain on sale of property, plant and equipment-(36)Non-GAAP Net (Loss) Income§(26,174)\$Capital expenditures11,9748,888				
Non-cash net interest expense234238Deferred revenue(725)696Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(26)-Increase in the fair value of contingent consideration(1,200)-Change in the fair value of common stock warrants318-Gain on sale of property, plant and equipment-(36)Non-GAAP Net (Loss) Income§(26,174)\$Capital expenditures11,9748,888			-	
Deferred revenue(725)696Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(26)-Increase in the fair value of contingent consideration(1,200)-Change in the fair value of common stock warrants318-Gain on sale of property, plant and equipment-(36)Non-GAAP Net (Loss) Income\$ (26,174) \$ 3,899Capital expenditures11,9748,888				
Net (gain) loss on transactions with equity method investee(397)603Gain on the Gainesville Transaction(26)-Increase in the fair value of contingent consideration(1,200)-Change in the fair value of common stock warrants318-Gain on sale of property, plant and equipment-(36)Non-GAAP Net (Loss) Income\$ (26,174) \$ 3,8993,899Capital expenditures11,9748,888	•			
Gain on the Gainesville Transaction(26)Increase in the fair value of contingent consideration(1,200)Change in the fair value of common stock warrants318Gain on sale of property, plant and equipment-Non-GAAP Net (Loss) Income\$ (26,174) \$ 3,899Capital expenditures11,974				
Increase in the fair value of contingent consideration(1,200)Change in the fair value of common stock warrants318Gain on sale of property, plant and equipment-Non-GAAP Net (Loss) Income\$ (26,174) \$ 3,899Capital expenditures11,974	·- ·		· · · · ·	603
Change in the fair value of common stock warrants318Gain on sale of property, plant and equipment-Non-GAAP Net (Loss) Income\$Capital expenditures11,9748,888				-
Gain on sale of property, plant and equipment-(36)Non-GAAP Net (Loss) Income\$(26,174)\$3,899Capital expenditures11,9748,888				-
Non-GAAP Net (Loss) Income \$ (26,174) \$ 3,899   Capital expenditures 11,974 8,888			318	-
Capital expenditures 11,974 8,888			-	
		\$		
Free Cash Outflow \$ (38,148) \$ (4,989)				
	Free Cash Outflow	\$	(38,148) \$	(4,989)

# Alkermes plc and Subsidiaries Selected Financial Information (Unaudited)

Revenues: 355.978 \$ 355.978 \$ 373.674   Product sales, net 106.212 64.476   Research and development revenues 3.047 5.478   Total Revenues 445.237 443.628   Expenses: 220.718 197.610   Seling, general and administrative 224.086 145.101   Anortization of acquired intagible asets 43.479 42.900   Total Expenses 622.481 515.084   Operating Loss (157.244) (114.456)   Other Income, net: 2.320 1.380   Interest income 2.330 1.380   Interest income 2.320 1.5246   Gain on sale of investment in Acceleron Pharma Inc. 2.320 1.5296   Gain on sale of investment in Acceleron Pharma Inc. 1.003 (2.253)   Total Other Income, net 1.003 (2.253)   Cober Income (expense), net 1.003 (2.253)   Total Other Income net 6.569 5.766   Non-GAAP (loss) earnings per share — basic \$ (0.21) \$ 0.25   (Loss) Earnings Per Sha	Condensed Consolidated Statements of Operations - GAAP (In thousands, except per share data)		Nine Months Ended September 30, 2015	Nine Months Ended September 30, 2014
Product sales, net106,21264,476Research and development revenues $3,047$ $5,478$ Total Revenues $465,237$ $443,628$ Expenses: $240,86$ $104,198$ $129,468$ Cost of goods manufactured and sold $104,198$ $129,468$ Research and development $224,086$ $145,101$ Selling, general and administrative $224,086$ $145,101$ Amortization of acquired intangible assets $43,479$ $42,909$ Total Expenses $622,481$ $155,084$ Operating Loss $(157,244)$ $(71,456)$ Other Income, net: $9,937$ -Interest expense $(9,928)$ $(10,097)$ Gain on the Gainesville Transaction $9,937$ -Increase in the fair value of contingent consideration $2,700$ -Gain on sale of investment in Acceleron Pharma Inc $12,321$ Increase in Lenome Taxes $((151,212)$ $(4,647)$ Other Income, net- $10,003$ $(2,253)$ Total Other Income net- $12,321$ $(5,69)$ Icos Before Income Taxes $((151,212)$ $(4,802)$ Icos Bernings Per Share: $(0,211)$ $(0,221)$ $(0,225)$ Charles per share — basic and diluted $5$ $(0,21)$ $(0,225)$ Non-GAAP (loss) earnings per share — basic and contrading: $148,828$ $144,732$ Basic and diluted — CAAP $148,828$ $144,732$ Natice As Coordinaty Shares Outstanding: $148,828$ $144,732$ Diluted — Non-GAAP	Revenues:			
Research and development revenues 3,047 5,478   Total Revenues 465,237 443,628   Expenses: 129,464 Research and development 250,718 197,610   Selling, general and administrative 224,086 145,101 3,479 42,909   Total Expenses: 622,481 515,084 425,001 429,099   Total Expenses: 622,481 515,084 (157,244) (71,456)   Other Income, net: 1 (157,244) (71,456) (10,097)   Gain on sale of investment in Acceleron Pharma Inc. 2,320 1,380 (10,097)   Gain on sale of property, plant and equipment 1,003 (2,253) 1,647   Loss Before Income Taxes (157,212) (54,809) (157,581) \$ (60,575)   Interest income Taxes 1,003 (2,253) 1,647 1,003 (2,253)   Total Über Income, net 1,003 (157,581) \$ (60,575) (157,581) \$ (60,575)   Interest income Taxes 1,012 (54,809) (5,576) \$ 5,766 \$ (021)		\$		
Total Revenues446.237443,628Expenses:104,198129,464Cost of goods manufactured and sold104,198129,464Research and development224,086145,101Amortization of acquired intangible assets43,47942,909Total Expenses622,418515,084Operating Loss(157,244)(71,456)Other Income, net:2,3201,380Interest income2,3201,380Interest income2,3201,380Interest expense(9,928)(10,097)Gain on sale of investment in Acceleron Pharma Inc15,296Gain on sale of property plant and equipment-12,231Other income (expense), net1,003(2,253)Total Other Income, net-16,647Loss Before Income Taxes(157,781)\$ (60,575)(Loss) Earnings Per Share:5(0,21)\$ (0,22)(GAAP loss) enrigs per share — basic and diluted\$ (100)\$ (0,21)\$ 0,225Non-GAAP (loss) earnings per share — basic\$ (0,21)\$ 0,225Weighted Average Number of Ordinary Shares Outstanding:148,828144,732Basic — Non-GAAP148,828144,732Diluted — ConAP\$ (14,732148,037Adjustments:70,41746,238Amortization expense70,41746,238Non-GAAP148,828144,732Diluted — Non-GAAP148,828144,732Diluted — Non-GAAP148,828144,732Diluted — Non-GAAP				
Expenses:104,198129,464Cost of goods manufactured and sold104,198129,464Research and development250,718197,610Selling, general and administrative24,086145,101Amortization of acquired intangible assets43,47942,909Total Expenses622,481515,084Operating Loss(157,244)(71,456)Other Income, net:15,2961,380Interest expense(9,928)(10,097)Gain on the Gainesville Transaction2,700-Gain on sale of property, plant and equipment.12,231Other Income (expense), net1,003(2,253)Total Depense), net.6,03216,647Loss Before Income Taxes(151,212)(54,809)Income Tax Provision6,5595,7665,7669Net Loss - GAAP\$ (151,7181) \$ (60,575)(0,22)(Loss) Earnings Per Share:GAAP loss per share — basic and diluted\$ (0,21) \$ 0,25Weighted Average Number of Ordinary Shares Outstanding:148,828144,732Basic and diluted — GAAP148,828144,732An itemized reconcilation between net loss on a GAAP basis and non-GAAP net (loss)Diluted — Non-GAAP\$ (157,781) \$ (60,575).Adustments:Net Loss — GAAP\$ (157,781) \$ (60,575)Net Loss — GAAPDiluted — Non-GAAP	Research and development revenues			
Cost of goods manufactured and sold104,198129,464Rescarch and development250,718197,610Selling, general and administrative244,086145,101Amortization of acquired intangible assets43,47942,909Total Expenses622,481515.084Operating Loss(157,244)(71,456)Other Income, net:2,3201,380Interest income2,3201,380Interest income2,3201,380Interest income2,700-Gain on the Gainesville Transaction2,700-Gain on sale of investment in Acceleron Pharma Inc15,296Gain on sale of property, plant and equipment-12,321Other Income, net1,003(2,253)Total Other Income, net6,6595,766Net Loss - GAAP\$(157,781)(GAAP loss per share — basic and diluted\$(0.21)Non-GAAP (loss) earnings per share — basic\$(0.21)Sasic and diluted - GAAP148,828144,732Basic and diluted - GAAP148,828144,732Basic and diluted - GAAP148,828154,017An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)144,732An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)1,627An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)144,732Interized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)144,732Diluted - Non			465,237	443,628
Research and development250,718197,610Selling, general and administrative224,086145,101Amortization of acquired intangible assets43,47942,909Total Expenses622,481515,084Operating Loss(157,244)(71,456)Other Income, net:11Interest expense(9,928)(10,097)Gain on the Gainesville Transaction9,937-Increase in the fair value of contingent consideration2,700-Gain on sale of property, plant and equipment-12,321Other Income (expense), net1,003(2,253)Total Other Income, net6,03216,647Loss Before Income faxes(151,212)(54,809)Income Tax Provision6,5595,766Net Loss - GAAP\$(157,781)\$(Loss) Earnings Per Share:(0,42)\$0,221GAAP loss) per share - basic and diluted\$(0,21)\$0,225Weighted Average Number of Ordinary Shares Outstanding:148,828144,732Basic and Mitted - GAAP148,828144,732144,732Basic and fulted - GAAP148,828144,732144,732Diluted - Non-GAAP\$(157,781)\$(60,575)Adjustments:\$0,211\$0,255Non-GAAP\$(157,781)\$(60,575)Adjustments:\$144,732144,732Basic - Non-GAAP\$148,828154,017An itemized reconciliation between			104 109	120 464
Selling, general and administrative224,086145,101Amortization of acquired intangible assets43,47942,909Total Expenses622,481515,084Operating Loss(157,244)(71,456)Other Income, net:1157,244)(71,456)Interest income2,3201,380Interest expense(9,928)(10,097)Gain on the Gainesville Transaction9,937-Gain on sale of investment in Acceleron Pharma Inc15,296Gain on sale of property, plant and equipment-12,321Other income (expense), net1,003(2,253)Total Other Income, net6,03216,647Loss Before Income Taxes(151,212)(54,809)Income Tax Provision6,5595,766Net Loss - GAAP\$(1021)\$Non-GAAP (loss) earnings per share — basic\$(0,21)\$Non-GAAP (loss) earnings per share — basic\$(0,21)\$0.265Weighted Average Number of Ordinary Shares Outstanding:148,828144,732\$Basic — Non-GAAP148,828144,732\$144,732Diluted — Non-GAAP148,828144,732\$144,732Diluted - Non-GAAP148,828154,017An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)16,0575Anjustments:\$(157,781) \$(60,575)Anitemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)148,828154,017An itemized reconci				
Amortization of acquired intangible assets43,47942,009Total Expenses622,481515,084Operating Loss(157,244)(71,456)Other Income, net:2,3201,380Interest expense(9,928)(10,097)Gain on the Gainesville Transaction9,937-Increase in the fair value of contingent consideration2,700-Gain on sale of property, plant and equipment-15,296Other income (expense), net1,003(2,233)Total Other Income, net6,03216,647Loss Before Income Taxes(151,212)(54,809)Income Tax Provision6,5695,766Net Loss - GAAP\$(157,781) \$(Loss) Earnings Per Share:G(0,21) \$GAAP loss per share — basic and diluted\$(0,21) \$Outed intenzione of Ordinary Shares Outstanding:Basic — Non-GAAP148,828Basic and diluted — Non-GAAP148,828144,732Diluted — Non-GAAP\$(157,781) \$(60,575)Adjustments:\$148,828144,732Basic and Sollows:\$(157,781) \$(60,575)Adjustments:\$9,447346,238Amortization expense74,47346,238Amortization expense705717Defreid revenue(1,627)(60,775)Non-cash net interest expense705717Defreid revenue(1,627)(60,575)Non-cash net interest expense705717Diluted — Non				
Total Expenses $622,481$ $515,084$ Operating Loss $(157,244)$ $(71,456)$ Other Income, net: $(157,244)$ $(71,456)$ Interest expense $(9,928)$ $(10,097)$ Gain on fle Gainesville Transaction $9,937$ .Increase in the fair value of contingent consideration $2,700$ .Gain on sale of investment in Acceleron Pharma IncGain on sale of property, plant and equipmentOther Income, net1,003(2,253)Total Other Income, netLoss Before Income TaxesIncome Tax ProvisionSefore Income Taxes(Loss) Earnings Per Share:(GAAP loss per share — basic and diluted\$.Non-GAAP (loss) earnings per share — basicBasic and diluted — GAAPBasic and diluted — GAAPAn itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss).Income Tax es follows:Non-GAAPBasic and sollows:Net Loss — GAAP\$.Mainterized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)Income tax es follows:.Non-cash net interest expense.Non-cash net interest expense.Adjustments:.Share-based compensation expense.Adjustments:.Share-based com				
Operating Loss(157,244)(71,456)Other Income, net:2,3201,380Interest income2,3201,380Interest income2,3201,380Interest expense(9,928)(10,097)Gain on the Gainesville Transaction2,700.Gain on sale of investment in Acceleron Pharma IncOther income (expense), net1,003(2,253)Total Other Income (expense), net1,003(6,2253)Income Taxes(151,212)(54,809)Income Tax Provision6,559\$,766Net Loss — GAAP\$ (1.06) \$ (0.42)Non-GAAP (loss) earnings per share — basic\$ (0.21) \$ 0.25Weighted Average Number of Ordinary Shares Outstanding:Basic — Non-GAAPBasic and diluted — GAAP148,828144,732Diluted — Non-GAAP148,828144,732Diluted — Non-GAAP\$ (157,781) \$ (60,575)Adjustments:\$ (157,781) \$ (60,575)An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)Income as follows:\$ (157,781) \$ (60,575)Adjustments:\$ (157,781) \$ (60,575)Adjustments:\$ (157,781) \$ (60,575)Non-cash net interest expense74,473Ad,47942,909Depreciation expense43,479Ad,20829,810Non-cash net interest expense705Non-cash net interest expense705Non-cash net interest expense705Non-cash net interest expense705Non-cash net interest exp				
Other Income, net:2,3201,380Interest expense(9,928)(10,097)Gain on the Gainesville Transaction9,937.Gain on sale of investment in Acceleron Pharma Inc.2,700.Gain on sale of property, plant and equipment.12,321Other income (expense), net1,003(2,253)Total Other Income, net6,03216,647Loss Before Income Taxes(151,212)(54,809)Income Tax Provision6,5695,766Net Loss — GAAP\$ (157,781)\$ (60,575)(Loss) Earnings Per Share:\$ (1006)\$ (0,42)GAAP loss per share — basic and diluted\$ (0,21)\$ 0,225Non-GAAP (loss) earnings per share — basic\$ (0,21)\$ 0,225Non-GAAP (loss) earnings per share — basic\$ (0,21)\$ 0,225Weighted Average Number of Ordinary Shares Outstanding:Basic and diluted — GAAP148,828Basic and diluted — GAAP148,828144,732Diluted — Non-GAAP148,828144,732Diluted — Non-GAAP148,828144,732Share-based compensation expense74,47346,238Amortization expense74,47346,238Amortization expense705717Deferred revenue(16,27)(60,575)Non-cash net interest expense705717Deferred revenue(16,27)(60,770)Net revenue(16,270)0,055Non-cash net interest expense705717Deferred revenue(16,270)0,055<				
Interest income2,3201,380Interest expense(9,928)(10,097)Gain on Ke Gainesville Transaction9,937-Increase in the fair value of contingent consideration2,700-Gain on sale of investment in Acceleron Pharma Inc15,296Gain on sale of property, plant and equipment-12,321Other income (expense), net1,003(2,253)Total Other Income, net6,03216,647Loss Before Income Taxes(151,212)(54,809)Income Tax Provision6,5595,766Net Loss - GAAP\$(157,781)\$(GAAP loss per share — basic and diluted\$(0.21)\$0.26Non-GAAP (loss) earnings per share — basic\$(0.21)\$0.25Weighted Average Number of Ordinary Shares Outstanding:Basic and diluted — GAAP148,828144,732Basic and diluted — Non-GAAP148,828144,732144,828144,732Diluted — Non-GAAP148,828144,732144,828154,017An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)income is as follows:(60,575)Not-cash text74,47346,23843,47942,909Depreciation expense20,33629,810Non-cash text interest expense705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(2,700)-Charge in the fair value of			(137,244)	(71,430)
Interest expense $(9,928)$ $(10,097)$ Gain on the Gainesville Transaction9,937-Increase in the fair value of contingent consideration2,700-Gain on sale of investment in Acceleron Pharma Inc15,296Gain on sale of property, plant and equipment-12,321Other income (expense), net1,003(2,253)Total Other Income, net6,03216,647Loss Before Income Taxes(151,212)(54,809)Income Tax Provision6,5695,766Net Loss — GAAP\$(105,781)\$(Loss) Earnings Per Share:GAAP loss per share — basic and diluted\$(0.42)Non-GAAP (loss) earnings per share — basic\$(0.21)\$Non-GAAP (loss) earnings per share — diluted\$(0.21)\$0.25Weighted Average Number of Ordinary Shares Outstanding:-148,828144,732Basic — Non-GAAP148,828144,732144,732144,732Diluted — Non-GAAP148,828144,732144,732An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)-(60,575)Adjustments:-\$(15,781) \$(60,575)Share-based compensation expense74,47346,238Amortization expense20,33629,810Non-cash nets705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on			2 320	1 380
Gain on the Gainesville Transaction9,937Increase in the fair value of contingent consideration2,700Gain on sale of investment in Acceleron Pharma Inc.15,296Gain on sale of property, plant and equipment12,321Other income (expense), net1,003Income Tax Provision6,032Income Tax Provision6,569States5,766Net Loss Before Income Taxes(151,212)(Iss) Before Income Taxes(60,575)(Loss) Earnings Per Share:(10,0)GAAP loss per share — basic and diluted\$Non-GAAP (loss) earnings per share — basic\$(Data) S additional per share — basic\$Meighted Average Number of Ordinary Shares Outstanding:Basic and diluted — GAAP148,828Basic — Non-GAAP148,828Diluted — Non-GAAP148,828An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)income is as follows:70,473Non-cash next interest expense74,473An oritzation expense43,479Anorization expense70,36Non-cash next interest expense70,571Non-cash next interest expense70,571Non-cash next interest expense70,571Non-cash next interest expense70,571Non-cash net interest expense70,571Non-cash interest expense70,571Non-cash interest expense70,571Non-cash net interest expense70,571Non-cash interest expense70,571Non-cash interest expe				
Increase in the fair value of contingent consideration2,700Gain on sale of investment in Acceleron Pharma Inc 15,296Gain on sale of property, plant and equipment. 12,321Other income (expense), net1,003Loss Before Income Taxes(151,212)Income Tax Provision6,569Net Loss — GAAP\$ (157,781)GAAP loss per share: $(10,0)$ GAAP loss per share — basic and diluted\$ (0,021)Non-GAAP (loss) earnings per share — basic\$ (0,21)Non-GAAP (loss) earnings per share — diluted\$ (0,21)Basic and diluted — GAAP148,828Basic and diluted — GAAP148,828Basic and diluted — GAAP148,828Item Von-GAAP148,828Item Von-GAAP148,828Diluted — Non-GAAP148,828Item Von-GAAP148,828Item Von-GAAP148,828Diluted — Non-GAAP148,828Net Loss — GAAP\$ (157,781)Net Loss — GAAP\$ (157,781)Agiustments:\$ (157,781)Share-based compensation expense74,473Ade,23843,479AgoyoDepreciation expenseAdato expense705Non-cash taxes9,199Non-cash taxes705Non-cash taxes705Non-cash taxes9,0937)Net (gain) loss on transactions with equity method investee(1,191)Net (gain) loss on transactions with equity method investee(1,191)Non-cash taxes9,0937)Non-cash taxes705 <td></td> <td></td> <td></td> <td>(10,0)7)</td>				(10,0)7)
Gain on sale of investment in Acceleron Pharma Inc.15,296Gain on sale of property, plant and equipment1,003Other income (expense), net1,003Itotal Other Income, net6,032Loss Before Income Taxes(151,212)(Ist,212)(54,809)Income Tax Provision6,569Net Loss - GAAP\$ (157,781) \$ (60,575)(Loss) Earnings Per Share: $(0.21)$ \$ 0.25(GAAP loss) earnings per share - basic and diluted\$ (0.21) \$ 0.25Non-GAAP (loss) earnings per share - diluted\$ (0.21) \$ 0.25Weighted Average Number of Ordinary Shares Outstanding:Basic and diluted - GAAP148,828Basic and diluted - GAAP148,828Intemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)Intemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)Intemized so (00, 575)Adjustments:Share-based compensation expense74,47346,238Amortization expense74,47346,238Non-cash taxes9101112131414141515151617181819191010101011111112131414141414 <tr< td=""><td></td><td></td><td></td><td>_</td></tr<>				_
Gain on sale of property, plant and equipment12,321Other income (expense), net1,003(2,233)Total Other Income, net6,03216,647Loss Before Income Taxes(151,212)(54,809)Income Tax Provision6,5695,766Net Loss — GAAP\$(157,781)\$(Loss) Earnings Per Share:(150,212)(54,809)GAAP loss per share — basic and diluted\$(0,21)\$Non-GAAP (loss) earnings per share — basic\$(0,21)\$Non-GAAP (loss) earnings per share — diluted\$(0,21)\$0.25Weighted Average Number of Ordinary Shares Outstanding:Basic and diluted — GAAP148,828144,732Basic and diluted — GAAP148,828144,732144,828144,732Diluted — Non-GAAP148,828154,017An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)Income is as follows:9(157,781)\$(60,575)Adjustments:74,47346,23843,47942,909Depreciation expense74,47346,23829,810Non-cash net interest expense7057175,055Non-cash net interest expense705717Defered revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(9,937)-Increase in the fair value of contingent consideration(2,700)-Change in the fair value of contingent conside			_,,	15,296
Other income (expense), net1,003(2,253)Total Other Income, net6,03216,647Loss Before Income Taxes(151,212)(54,809)Income Tax Provision6,5695,766Net Loss — GAAP\$(157,781) \$(60,575)(Loss) Earnings Per Share: $(157,781) $(0,21) $0.26Non-GAAP (loss) earnings per share — basic$(0.21) $0.26Non-GAAP (loss) earnings per share — basic$(0.21) $0.25Weighted Average Number of Ordinary Shares Outstanding:Basic and diluted — GAAP148,828144,732Basic — Non-GAAP148,828144,732144,732Diluted — Non-GAAP148,828154,017An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)157,781) $(60,575)Adjustments:Share-based compensation expense74,47346,238Amortization expense74,47346,23841,499Amortization expense20,33629,810Non-cash net interest expense705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(2,700).Change in the fair value of contingent consideration(2,700).Change in the fair value of contingent consideration(2,700).$			-	
Total Other Income, net $6,032$ $16,647$ Loss Before Income Taxes $(151,212)$ $(54,809)$ Income Tax Provision $6,569$ $5,766$ Net Loss — GAAP\$ $(157,781)$ \$(GAAP loss) earnings Per Share:(GAAP loss) earnings per share — basic and diluted\$ $(1.06)$ \$Non-GAAP (loss) earnings per share — basic\$ $(0.21)$ \$ $0.26$ Non-GAAP (loss) earnings per share — diluted\$ $(0.21)$ \$ $0.25$ Weighted Average Number of Ordinary Shares Outstanding:Basic and diluted — GAAP148,828144,732Basic — Non-GAAP148,828144,732144,732Diluted — Non-GAAP148,828154,017An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$ $(1.57,781)$ \$Net Loss — GAAP\$ $(157,781)$ \$ $(60,575)$ Adjustments:\$ $74,473$ 46,238Amortization expense $20,336$ $29,810$ Non-cash net interest expense $705$ $717$ Deferred revenue $(1,627)$ $(607)$ Non-cash net interest expense $705$ $717$ Deferred revenue $(1,627)$ $(607)$ Net (gain) loss on transactions with equity method investee $(1,191)$ $1,842$ Gain on Gainesville Transaction $(2,700)$ $(2,700)$ $(558)$ Change in the fair value of contingent consideration $(2,700)$ $(558)$ $(558)$			1,003	
Loss Before Income Taxes $(151,212)$ $(54,809)$ Income Tax Provision6,5695,766Net Loss — GAAP\$ $(157,781)$ \$ $(60,575)$ (Loss) Earnings Per Share:GAAP loss per share — basic and diluted\$ $(121)$ \$ $(0.42)$ Non-GAAP (loss) earnings per share — basic\$ $(0.21)$ \$ $0.26$ Non-GAAP (loss) earnings per share — diluted\$ $(0.21)$ \$ $0.25$ Weighted Average Number of Ordinary Shares Outstanding:Basic and diluted — GAAP148,828Basic — Non-GAAP148,828144,732Diluted — Non-GAAP148,828144,732Diluted — Non-GAAP148,828154,017An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)60,575)Adjustments:S (157,781) \$ (60,575)Adjustments:74,47346,238Amortization expense43,47942,909Depreciation expense20,33629,810Non-cash taxes4,1995,055Non-cash net interest expense705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(9,937)-Increase in the fair value of common stock warrants(558)-				
Income Tax Provision6,5695,766Net Loss — GAAP\$ (157,781) \$ (60,575)(Loss) Earnings Per Share: $(1.06) $ (1.27,781) $ (0.21$				
Net Loss - GAAP\$ (157,781)\$ (60,575)(Loss) Earnings Per Share:GAAP loss per share basic and diluted\$ (1.06)\$ (0.42)Non-GAAP (loss) earnings per share basic\$ (0.21)\$ 0.26Non-GAAP (loss) earnings per share diluted\$ (0.21)\$ 0.25Weighted Average Number of Ordinary Shares Outstanding:Basic and diluted GAAP148,828144,732Basic Non-GAAP148,828144,732Diluted Non-GAAP148,828154,017An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)income is as follows:\$ (157,781)\$ (60,575)Adjustments:\$ (157,781)\$ (60,575)Adjustments:\$ (157,781)\$ (60,575)Non-cash taxes43,47942,909Depreciation expense20,33629,810Non-cash net interest expense705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(2,700)-Change in the fair value of contingent consideration(2,700)-Change in the fair value of common stock warrants(558)-				
(Loss) Earnings Per Share:GAAP loss per share — basic and diluted\$ (1.06) \$ (0.42)Non-GAAP (loss) earnings per share — basic\$ (0.21) \$ 0.25Weighted Average Number of Ordinary Shares Outstanding:\$ (0.21) \$ 0.25Basic and diluted — GAAP148,828Basic — Non-GAAP148,828Diluted — Non-GAAP148,828Diluted — Non-GAAP148,828Sincome is as follows:148,828Note Loss — GAAP\$ (157,781) \$ (60,575)Adjustments:\$ (157,781) \$ (60,575)Adjustments:\$ (157,781) \$ (60,575)Adjustments:\$ (157,781) \$ (60,575)Non-cash taxes\$ 43,479Appende\$ 20,336Share-based compensation expense\$ 43,479Appende\$ 20,336Share-based compensation expense\$ 14,199Share-based compense\$ 14,199Share-based compense\$ 14,199Share-based compense\$ 14,199Share-based compense\$ 14,199Share-based compense\$ 14,199Share-based compense\$ 14,297Cain on cainexylle transactions with equity method investee\$ 11,911Share-based compense\$ 14,297Basic and the fair value of contingent consideration\$ 14,293Cain on Gainesylle Transac		¢		
GAAP loss per share — basic and diluted\$ (1.06) \$ (0.42)Non-GAAP (loss) earnings per share — basic\$ (0.21) \$ 0.26Non-GAAP (loss) earnings per share — diluted\$ (0.21) \$ 0.25Weighted Average Number of Ordinary Shares Outstanding: Basic and diluted — GAAP148,828Basic — Non-GAAP148,828Diluted — Non-GAAP148,828Diluted — Non-GAAP148,828Share-Dased compensation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$ (157,781) \$ (60,575)Net Loss — GAAP\$ (157,781) \$ (60,575)Adjustments: Share-based compensation expense74,473Ade,23843,479Amortization expense20,33620,33629,810Non-cash taxes4,1995,055Non-cash taxesNon-cash taxes705Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(2,700)Increase in the fair value of contingent consideration(2,700)Change in the fair value of common stock warrants(558)		- <sup>э</sup> .	(107,701) 5	(00,575)
Non-GAAP (loss) earnings per share — basic\$ $(0.21)$ \$ $0.26$ Non-GAAP (loss) earnings per share — diluted\$ $(0.21)$ \$ $0.25$ Weighted Average Number of Ordinary Shares Outstanding: Basic and diluted — GAAP $148,828$ $144,732$ Basic — Non-GAAP $148,828$ $144,732$ Diluted — Non-GAAP $148,828$ $144,732$ An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$ $(157,781)$ \$Net Loss — GAAP\$ $(157,781)$ \$ $(60,575)$ Adjustments: Share-based compensation expense $74,473$ $46,238$ Amortization expense $74,473$ $46,238$ Amortization expense $20,336$ $29,810$ Non-cash taxes $4,199$ $5,055$ Non-cash taxes $705$ $717$ Deferred revenue $(1,627)$ $(607)$ Net (gain) loss on transactions with equity method investee $(1,191)$ $1.842$ Gain on Gainesville Transaction $(2,700)$ $(2,700)$ $(558)$ Increase in the fair value of contingent consideration $(2,700)$ $(558)$ $(558)$	(Loss) Earnings Per Share:			
Non-GAAP (loss) earnings per share — diluted\$ (0.21) \$ 0.25Weighted Average Number of Ordinary Shares Outstanding: Basic and diluted — GAAP148,828144,732Basic — Non-GAAP148,828144,732Diluted — Non-GAAP148,828144,732Diluted — Non-GAAP148,828154,017An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$ (157,781) \$ (60,575)Adjustments: Share-based compensation expense74,47346,238Amortization expense74,47346,238Amortization expense20,33629,810Non-cash taxes41,995,055Non-cash net interest expense705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(2,700)-Change in the fair value of common stock warrants(558)-	GAAP loss per share — basic and diluted	\$		
Non-GAAP (loss) earnings per share — diluted\$ (0.21) \$ 0.25Weighted Average Number of Ordinary Shares Outstanding: Basic and diluted — GAAP148,828Basic and diluted — GAAP148,828Basic — Non-GAAP148,828Diluted — Non-GAAP148,828Itale — Non-GAAP148,828Share-based conciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$ (157,781) \$ (60,575)Net Loss — GAAP\$ (157,781) \$ (60,575)Adjustments: Share-based compensation expense74,47346,23843,479Amortization expense43,347942,90920,336Depreciation expense705Non-cash taxes4,1995,055Non-cash net interest expenseNon-cash net interest expense705Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(2,700)-Change in the fair value of contingent consideration(2,700)Change in the fair value of common stock warrants(558)	Non-GAAP (loss) earnings per share — basic	\$		
Weighted Average Number of Ordinary Shares Outstanding:Basic and diluted — GAAP148,828144,732Basic — Non-GAAP148,828144,732Diluted — Non-GAAP148,828144,732An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:148,828154,017An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$ (157,781) \$ (60,575)Adjustments: Share-based compensation expense74,47346,238Amortization expense74,47346,238Amortization expense20,33629,810Non-cash taxes4,1995,055Non-cash net interest expense705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(2,700)-Increase in the fair value of contingent consideration(2,700)-Change in the fair value of common stock warrants(558)-		\$	(0.21) \$	0.25
Basic and diluted — GAAP148,828144,732Basic — Non-GAAP148,828144,732Diluted — Non-GAAP148,828154,017An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:148,828154,017Net Loss — GAAP\$ (157,781) \$ (60,575)Adjustments:\$ (157,781) \$ (60,575)Share-based compensation expense74,47346,238Amortization expense43,47942,909Depreciation expense20,33629,810Non-cash taxes4,1995,055Non-cash net interest expense705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(2,700)-Increase in the fair value of contingent consideration(2,700)-Change in the fair value of common stock warrants(558)-				
Basic and and the or har148,828144,732Basic — Non-GAAP148,828154,017Diluted — Non-GAAP148,828154,017An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:\$ (157,781) \$ (60,575)Net Loss — GAAP\$ (157,781) \$ (60,575)Adjustments:Share-based compensation expense74,473Amortization expense20,33629,810Non-cash taxes4,1995,055Non-cash net interest expense705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(2,700)-Increase in the fair value of contingent consideration(2,700)-Change in the fair value of common stock warrants(558)-			140.000	144 722
DateHor OrtriDiluted — Non-GAAP148,828An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss) income is as follows:(60,575)Net Loss — GAAP\$ (157,781) \$ (60,575)Adjustments:74,473Share-based compensation expense74,473Amortization expense20,336Depreciation expense20,336Non-cash taxes4,199Solor5,055Non-cash net interest expense705Offerred revenue(1,627)Offerred revenue(1,627)Cain on Gainesville Transaction(9,937)Increase in the fair value of contingent consideration(2,700)Change in the fair value of common stock warrants(558)				
An itemized reconciliation between net loss on a GAAP basis and non-GAAP net (loss)income is as follows:\$ (157,781) \$ (60,575)Net Loss — GAAP\$ (157,781) \$ (60,575)Adjustments:74,473Share-based compensation expense74,473Amortization expense20,336Depreciation expense20,336Non-cash taxes4,199Non-cash net interest expense705Non-cash net interest expense705Non-cash net interest expense705Not (gain) loss on transactions with equity method investee(1,627)Gain on Gainesville Transaction(9,937)Increase in the fair value of contingent consideration(2,700)Change in the fair value of common stock warrants(558)				
income is as follows: Net Loss — GAAP \$ (157,781) \$ (60,575) Adjustments: Share-based compensation expense 74,473 46,238 Amortization expense 43,479 42,909 Depreciation expense 20,336 29,810 Non-cash taxes 4,199 5,055 Non-cash net interest expense 705 717 Deferred revenue (1,627) (607) Net (gain) loss on transactions with equity method investee (1,191) 1,842 Gain on Gainesville Transaction (9,937) - Increase in the fair value of contingent consideration (2,700) - Change in the fair value of common stock warrants (558) -	Diluted — Non-GAAP		148,828	154,017
Net Loss — GAAP\$ (157,781) \$ (60,575)Adjustments:Share-based compensation expense74,47346,238Amortization expense43,47942,909Depreciation expense20,33629,810Non-cash taxes4,1995,055Non-cash net interest expense705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(9,937)-Increase in the fair value of contingent consideration(2,700)-Change in the fair value of common stock warrants(558)-				
Adjustments:74,47346,238Share-based compensation expense74,47346,238Amortization expense43,47942,909Depreciation expense20,33629,810Non-cash taxes4,1995,055Non-cash net interest expense705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(9,937)-Increase in the fair value of contingent consideration(2,700)-Change in the fair value of common stock warrants(558)-		\$	(157,781) \$	(60,575)
Amortization expense43,47942,909Depreciation expense20,33629,810Non-cash taxes4,1995,055Non-cash net interest expense705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(9,937)-Increase in the fair value of contingent consideration(2,700)-Change in the fair value of common stock warrants(558)-		+	× , , , , ,	( , , ,
Depreciation expense20,33629,810Non-cash taxes4,1995,055Non-cash net interest expense705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(9,937)-Increase in the fair value of contingent consideration(2,700)-Change in the fair value of common stock warrants(558)-	Share-based compensation expense			
Non-cash taxes4,1995,055Non-cash net interest expense705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(9,937)-Increase in the fair value of contingent consideration(2,700)-Change in the fair value of common stock warrants(558)-				
Non-cash net interest expense705717Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(9,937)-Increase in the fair value of contingent consideration(2,700)-Change in the fair value of common stock warrants(558)-	Depreciation expense			
Deferred revenue(1,627)(607)Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(9,937)-Increase in the fair value of contingent consideration(2,700)-Change in the fair value of common stock warrants(558)-				
Net (gain) loss on transactions with equity method investee(1,191)1,842Gain on Gainesville Transaction(9,937)-Increase in the fair value of contingent consideration(2,700)-Change in the fair value of common stock warrants(558)-				
Gain on Gainesville Transaction(9,937)-Increase in the fair value of contingent consideration(2,700)-Change in the fair value of common stock warrants(558)-				
Increase in the fair value of contingent consideration(2,700)Change in the fair value of common stock warrants(558)				1,842
Change in the fair value of common stock warrants (558) -				-
				-
			(558)	(15-200)
Gain on sale of investment in Acceleron Pharma Inc (15,296)			-	
Gain on sale of property, plant and equipment			(20.(02)	
Non-GAAP Net (Loss) Income \$ (30,602) \$ 37,772		\$		
Capital expenditures $36,730 = 20,326$	· ·	-		
Free Cash (Outflow) Inflow \$ (67,332) \$ 17,446	Free Cash (Outflow) Inflow	\$	(67,332) \$	17,446

# Alkermes plc and Subsidiaries Selected Financial Information (Unaudited)

Condensed Consolidated Balance Sheets (In thousands)	September 30, 2015	December 31, 2014	
Cash, cash equivalents and total investments	\$	815,499 \$	801,646
Receivables		140,987	151,551
Inventory		36,783	51,357
Prepaid expenses and other current assets		50,893	42,719
Property, plant and equipment, net		242,675	265,740
Intangible assets, net and goodwill		486,266	573,624
Contingent consideration		60,300	-
Other assets		47,552	34,635
Total Assets	\$	1,880,955 \$	1,921,272
Long-term debt — current portion	\$	66,712 \$	6,750
Other current liabilities		133,690	123,832
Long-term debt		286,512	351,220
Deferred revenue — long-term		7,477	11,801
Other long-term liabilities		19,759	30,832
Total shareholders' equity		1,366,805	1,396,837
Total Liabilities and Shareholders' Equity		1,880,955 \$	1,921,272
		1 10 50 1	1 1 = 5 2 0
Ordinary shares outstanding (in thousands)		149,584	147,539

This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2015, which the company intends to file in October 2015.